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 Abstract 
 In the circulation 25-hydroxyvitamin D (25(OH)D) is bound to vitamin D-binding protein (DBP) and albumin. Only a 
small fraction is in the unbound, free form. According to the  ‘ free-hormone-hypothesis ’ only the free form is biologically 
active. Genetic differences in DBP may affect the binding to 25(OH)D and thereby the amount of free 25(OH)D. In the 
present study sera were obtained from 265 postmenopausal women with low bone mass density (BMD). Serum 25(OH)
D, DBP and albumin were measured and the free and bio-available (free  ! albumin-bound) 25(OH)D calculated. Based 
on genotyping of the polymorphisms rs7041 and rs4588, the six common DBP phenotypes were identifi ed and the free 
and bio-available 25(OH)D calculated according to the corresponding binding coeffi cients. Relations between measures of 
25(OH)D and PTH and BMD were evaluated with linear regression adjusted for age and BMI. The calculated amount of 
free and bio-available 25(OH)D was 0.03% and 13.1%, respectively, of the measured total serum 25(OH)D. Adjusting for 
DBP phenotype affected the calculated free and bio-available 25(OH)D levels up to 37.5%. All measures of 25(OH)D 
correlated signifi cantly with PTH, whereas a signifi cant association with BMD was only seen for the free and bio-available 
25(OH)D measures. Adjusting for the DBP phenotypes improved the associations. These relations were almost exclusively 
seen in subjects not using vitamin D and/or calcium supplements. In conclusion, the free and bio-available forms of 25(OH)
D may be a more informative measure of vitamin D status than total 25(OH)D. Adjustment for DBP phenotype may 
improve this further. 
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 Introduction 
 Vitamin D is both a hormone and a vitamin. It can 
be obtained from the diet or produced endogenously 
from 7-dehydrocholesterol in the skin during UVB 
exposure. Vitamin D is hydroxylated in the liver to 
25-hydroxyvitamin D (25(OH)D), the metabolite 
used to evaluate the vitamin D status. Further hydrox-
ylation to 1,25-dihydroxyvitamin D (1,25(OH) 2 D), 
the active metabolite, takes place in the kidneys [1]. 
The vitamin D metabolites are transported in the 
circulation by vitamin D-binding protein (DBP) 
which is a water-soluble carrier-protein. About 85 – 90% 
of 25(OH)D and 1,25(OH) 2 D are bound to DBP. 
A considerable amount is also bound to albumin and 
less than 1% of 25(OH)D and 1,25(OH) 2 D circulate 
in the bloodstream freely [2]. 
 According to the free-hormone hypothesis it is 
the free fraction of a hormone that is the biological 
active component. Because albumin binds 25(OH)D 
weakly one may assume that 25(OH)D dissociates 
from albumin during tissue perfusion [3]. Therefore, 
bio-available 25(OH)D refers to the sum of the free 
and the albumin-bound fraction of 25(OH)D. If the 
free hormone hypothesis holds true for vitamin D 
metabolites, one should expect that the free and/or 
bio-available fractions would correlate more strongly 
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with biological actions of vitamin D than the total 
serum 25(OH)D. 
 1,25(OH) 2 D increases calcium absorption in 
the intestines and reabsorption in the kidneys. It 
also increases calcium reabsorption in bone, and 
together with increased calcium levels, this inhibits 
parathyroid hormone (PTH) secretion from the 
parathyroid gland [4]. PTH increases osteoclast 
activity [5]. Thus, adequate vitamin D levels are 
important for bone health by ensuring suffi cient 
inhibition of PTH secretion. There is also evidence 
that vitamin D metabolites have multiple other bio-
logical effects like maintaining the immune system 
[6], preventing cardiovascular disease [7] and 
diabetes [8], and even decreased mortality [9]. In 
most [10 – 12] but not all studies [13,14] bone mass 
density (BMD) shows a positive correlation with 
vitamin D status. In the present study we wanted to 
test whether this association becomes stronger using 
the free and bio-available fraction of serum 25(OH)
D as compared to the total serum levels of 25(OH)
D. In addition, the impact of the free and bio-
available fraction of serum 25(OH)D on PTH levels 
were investigated. 
 DBP is a highly polymorphic protein with six 
major phenotypes, all with different binding affi nities 
for 25(OH)D [15]. These phenotypes are the results 
of two single nucleotide polymorphisms (SNPs) in 
the  DBP gene (globulin-complex gene,  GC gene), 
rs7041 and rs4588 [16]. We have therefore geno-
typed the subjects for these SNPs in order to apply 
the correct DBP binding coeffi cients for each indi-
vidual in the calculations of free and bio-available 
25(OH)D. 
 Materials and methods 
 Subjects 
 The blood samples were collected at baseline from 
post-menopausal women aged 50 – 80 years old who 
participated in an osteoporosis intervention study 
[17]. Among the 297 subjects included in the osteo-
porosis study, 32 were missing data needed to calcu-
late free 25(OH)D, leaving 265 subjects for the 
present analysis. The subjects were included from 
January 2007 until February 2009. All subjects had 
a T-score in total hip or lumbar spine  "  #  2. Exclu-
sion criteria relevant to this study were suspected 
hyperparathyroidism (serum calcium  $  2.55 mmol/L, 
serum calcium  $  2.50 mmol/L combined with plasma 
PTH  $  5.0 pmol/L, or serum calcium  $  2.45 mmol/L 
combined with plasma PTH  $  7.0 pmol/L). Further 
exclusion criteria were use of steroids, renal stone 
disease, systolic blood pressure  $  175 mmHg or dia-
stolic blood pressure  $  105 mmHg, serum creatinine 
 $  110  µ mol/L, chronic diseases like ischemic heart 
disease, diabetes, granulomatous disease, and cancer. 
No ethnic data were collected, but the large majority 
of the subjects were Caucasian and a few were Sami 
women. 
 Measurements 
 The subjects fi lled in a questionnaire on use of vita-
min D and calcium supplements. Height and weight 
were measured with light clothing and no shoes. 
Total body, total hip, and lumbar spine (L1-L4) 
BMD were measured using dual X-ray absorptiom-
etry (DEXA) (GE Lunar Prodigy, Lunar Corpora-
tion, Madison, WI, USA). 
 Serum was stored in aliquots at  #  70 ° C for later 
analyses of total serum 25(OH)D and DBP. Serum 
25(OH)D was measured at the Hormone Labora-
tory, Haukeland University Hospital, using an in-
house developed liquid chromatography double mass 
spectrometry method [18]. The reference range is 
50 – 113 nmol/L. The laboratory takes part in the 
external quality program DEQAS [19]. DBP was 
analyzed at the Hormone Laboratory, Aker Univer-
sity Hospital by an in house competitive radioim-
munoassay according to Kauppinen-M ä kelin et  al. 
[20], reference range 3.0 – 5.3  µ mol/L. 
 The other analyses were performed consecutively 
at the Department of Medical Biochemistry at the 
University Hospital of North Norway. Plasma PTH 
was measured using an automated clinical chemistry 
analyzer (Immulite 2000, Siemens Healthcare Diag-
nostics, Los Angeles, CA, USA), reference range 
1.1 – 7.5 pmol/L, and serum calcium was analyzed 
using an automated analyzer (Hitachi 917) with 
reagents from Boehringer Mannheim, reference 
range 2.15 – 2.55 mmol/L. Albumin was measured by 
a colorimetric method (bromcresol green) using an 
automated analyzer, Cobas 800 (c702, Roche Diag-
nostics, Mannheim, Germany). The method was 
standardized to reference material BCR470/CRM470 
from Institute for Reference Materials and Measure-
ments (IRMM, Geel, Belgium). The reference inter-
val was that elaborated jointly with The Nordic 
Reference Interval Project (NORIP), 18 – 39 years: 
36.0 – 48.0 g/L, 40 – 69 years: 36.0 – 45.0 g/L and  %  70 
years: 34.0 – 45.0 g/L. 
 DNA was prepared from whole blood. Genotyp-
ing was performed by KBioscience (http://www.
kbioscience.co.uk) using KBioscience Competitive 
Allele-Specifi c PCR genotyping system [21]. 
 Calculations of free and bio-available serum 25(OH)D 
 Calculations of free and albumin-bound 25(OH)D 
were done using a general formula developed by 
Vermeulen et  al. [22] and tailored for calculating 
free 25(OH)D by Powe et  al. [23]: 
 Free 25(OH)D  &  total 25(OH)D/((binding coef-
fi cient albumin  ' [albumin])  ! (binding coeffi cient 
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 Albumin-bound 25(OH)D  &  [free 25(OH)D] 
 ' binding coeffi cient albumin  ' [albumin]. 
 Bio-available 25(OH)D was calculated as the 
sum of free 25(OH)D and albumin-bound 25(OH)
D. The binding coeffi cient used for albumin 
was 6  '  10 5 and for DBP (without regard to DBP 
phenotype) 7  '  10 8 [2]. In order to assign binding 
coeffi cients for the various DBP (or Gc) phenotypes, 
the subjects were genotyped for the two SNPs rs7041 
and rs4588. For these two SNPs the following 




A TA (2) GA
C TC (1f) GC (1s)
 
 The GA- variant does not occur in humans on a 
regular basis, and therefore only the following diplo-
types are relevant: 
 
TA TC GC
TA TA-TA TA-TC TA-GC
TC TA-TC TC-TC GC-TC
GC TA-GC GC-TC GC-GC
 
 Based on the binding coeffi cients for Gc-1S, 
Gc-1F and Gc-2 [15], and the binding coeffi cient of 
combined haplotypes to be the mean of the two, the 
following binding coeffi cients for the specifi c 
DBP phenotypes were used in our calculations of 
 ‘ SNP-adjusted ’ free and bio-available 25(OH)D: 
 
Diplotype Phenotype Binding coeffi cient
GC/GC Gc-1S/Gc-1S 6  '  10 8 
GC/TC Gc-1S/Gc-1F 4.8  '  10 8 
GC/TA Gc-1S/Gc-2 8.6  '  10 8 
TC/TC Gc-1F/Gc-1F 3.6  '  10 8 
TC/TA Gc-1F/Gc-2 7.4  '  10 8 
TA/TA Gc-2/Gc-2 11.2  '  10 8 
 
 Statistics 
 Normal distribution was evaluated by assessing his-
tograms visually, and all variables were considered 
normally distributed. 
 Comparisons between groups were performed 
with Student ’ s paired and unpaired  t -tests. Linear 
regression was used to evaluate relations with 
adjustments for body mass index (BMI) and age. 
In this model the interaction between use of sup-
plements (calcium and/or vitamin D) and mea-
sures of serum 25(OH)D and BMD appeared 
( p  &  0.08). In this study, intake of cod liver oil was 
not included as a supplement as in Norway this 
most often is a life-long habit. Data are, where rel-
evant, presented for subjects with and without 
supplements. 
 The statistical analyses were performed with 
SPSS. All tests were done two-tailed and a  p -value 
 (  0.05 was considered statistically signifi cant. 
The data are shown as mean (SD) unless otherwise 
specifi ed. 
 Ethics 
 The study was approved by the Regional Committee 
for Medical and Health Research Ethics (REK 
Nord). 
 Results 
 Twenty-fi ve subjects were taking calcium supple-
ments alone, 18 subjects were taking vitamin D 
supplements alone, and 54 subjects were taking both 
calcium and vitamin D. In those taking calcium the 
mean supplement intake was 804 (268) mg/day, and 
in those taking vitamin D the mean supplement 
intake was 393 (247) IU/day. Although there 
appeared to be an interaction between use of supple-
ments, measures of serum 25(OH)D and BMD, the 
distribution curves for 25(OH)D, DBP and albumin 
appeared similar in users and non-users of supple-
ments (Supplementary Figures 1 – 15, available 
online at http://informahealthcare.com/doi/abs/
10.3109/00365513.2013.869701). One hundred 
and sixty-eight subjects had no supplements. The 
characteristics of the subjects are shown in Table I. 
As expected, serum calcium was signifi cantly higher, 
plasma PTH lower and measures of serum 25(OH)
D higher in those on supplements. In the subjects 
not taking supplements the free and bio-available 
25(OH)D were 0.03% and 13.1%, respectively, of 
the total serum 25(OH)D. 
 In those not using vitamin D supplements the 
mean serum 25(OH)D levels were non-signifi cantly 
higher in those included during the summer months 
(May – September) ( n  &  70) compared to those 
included during the winter months (October – April) 
( n  &  123) (70.1 [17.7] vs. 65.0 [23.4] nmol/L, respec-
tively), and similarly in those using vitamin D supple-
ments 84.2 (15.7) ( n  &  31) and 80.5 (26.5) nmol/L 
( n  &  41), respectively. 
 Using binding coeffi cients specifi c for the six DBP 
phenotypes ( ‘ SNP adjusting ’ ) had a considerable 
effect on the estimated serum free and bio-available 
25(OH)D levels. Thus, phenotype Gc-1S/Gc-2  ‘ SNP 
adjustment ’ led to a calculated increase in free 25(OH)
D of 37.5% and an increase in bio-available 25(OH)
D of 26.8%. For the phenotype Gc-1F/Gc-1F a 
decrease of 34.7% and 34.6% for calculated free 
25(OH)D and bio-available 25(OH)D, respectively, 
was found (Table II). The serum DBP differed accord-
ing to phenotype as expected [24], with the Gc-2/ 
Gc-2 phenotype having the lowest and the GC-1 































































180 M. S. Johnsen et al. 
 In the linear regression model with BMI and age 
as covariates, almost all the 25(OH)D measures 
correlated signifi cantly and similarly with plasma 
PTH, in both users and non-users of supplements. 
There were no signifi cant relations with serum cal-
cium and measures of serum 25(OH)D (data not 
shown). For BMD there were no signifi cant asso-
ciations with total 25(OH)D. In subjects not using 
supplements, all measures of free and bio-available 
25(OH)D had a signifi cant positive association with 
BMD total body. In this group, the  ‘ SNP-adjusted ’ 
free and bio-available 25(OH)D were also signifi -
cantly and positively associated with BMD total hip 
(Table III). Serum DBP was signifi cantly and nega-
tively associated with BMD total body and BMD 
total hip (Table III). No signifi cant relations were 
seen between serum albumin and BMD or PTH 
(Table III). 
 Discussion 
 The main objective of this study was to examine 
whether free or bio-available 25(OH)D would cor-
relate better with plasma PTH and BMD than total 
25(OH)D; and secondly, to examine if using specifi c 
binding coeffi cients for the different DBP pheno-
types in calculating the free and bio-available fraction 
of 25(OH)D would improve the results. 
 All measures of 25(OH)D had a strong and 
negative association with PTH. For BMD only the 
free and bio-available measures of 25(OH)D had a 
signifi cant positive association, whereas no signifi -
cant associations were seen for total 25(OH)D. 
Although comparisons of standardized beta coeffi -
cients should be done with caution, it is noteworthy 
that at the hip the standardized beta-coeffi cients 
were fi ve times higher for free and bio-available 
25(OH)D and BMD than what was observed for 
total 25(OH)D. It should be noted that these 
signifi cant associations were primarily seen in the 
subjects not using supplements. This is reasonable, 
as supplements will have a rapid effect on the serum 
25(OH)D levels, whereas an effect on bone will 
come more slowly. In line with this, the high and 
almost equal relation between all measures of serum 
25(OH)D and PTH refl ects the rapid response in 
PTH secretion to changes in vitamin D status, as 
that seen following vitamin D supplementation. 




( n  &  73
Gc-1S/ Gc-1F 
( n  &  59)
Gc-1S/ Gc-2 
( n  &  83)
Gc-2/Gc-2 
( n  &  12)
Gc-1F/Gc-2 
( n  &  22)
Gc-1F/ Gc-1F 
( n  &  16)
Serum total 25(OH)D (nmol(L) 75.9 (23.7) 73.0 (24.4) 69.3 (21.7) 62.2 (17.0) 61.0 (19.5) 70.4 (21.8)
Serum free 25(OH)D (pmol/L) 25.0 (8.3) 22.6 (7.8) 23.2 (7.6) 25.0 (7.2) 20.2 (5.8) 20.2 (6.6)
Serum free 25(OH)D 
 SNP adjusted (pmol/L)
28.6 (9.5) * 18.8 (6.5) * 31.9 (10.4) * 42.1 (11.9) * 19.2 (5.5) * 13.2 (4.3) * 
Serum bio-available 25(OH)D (nmol/L) 10.0 (3.4) 9.0 (3.0) 9.3 (3.0) 10.3 (3.1) 8.3 (2.3) 8.1 (2.7)
Serum bio-available 25(OH)D 
SNP adjusted (nmol/L)
11.5 (3.8) * 7.5 (2.5) * 12.8 (4.2) * 17.3 (5.1) * 7.9 (2.2) * 5.3 (1.8) * 
Serum DBP ( µ mol/L) 3.83 (0.53) 4.10 (0.57) 3.76 (0.54) 3.00 (0.31) 3.73 (0.54) 4.46 (0.59)
 * p  (  0.001 versus unadjusted measure. Student ’ s paired  t -test. 
 Table I. Characteristics of the subjects taking vitamin D and/or calcium supplements and the subjects 
not taking supplements. 
Subjects taking 
supplements ( n  &  97)
Subjects not taking 
supplements ( n  &  168)
Age (years) 61.8 (9.6) 63.3 (6.9)
BMI (kg/m 2 ) 24.8 (3.4) 24.7 (3.3)
Serum calcium (mmol/L) 2.37 (0.09) 2.35 (0.07) * 
Plasma PTH (pmol/L) 4.64 (1.43) 5.27 (1.76) * * 
Serum albumin (g/L) 44.5 (2.2) 44.4 (2.1)
Serum DBP ( µ mol/L) 3.79 (0.54) 3.90 (0.62)
BMD total body (g/cm #2 ) 1.007 (0.053) 0.997 (0.056)
BMD L1 – L4 (g/cm #2 ) 0.890 (0.071) 0.877 (0.066)
BMD total hip (g/cm #2 ) 0.791 (0.070) 0.789 (0.081)
Serum total 25(OH)D (nmol/L) 79.54 (22.20) 66.02 (21.70) * * * 
Serum albumin-bound 25(OH)D (nmol/L) 10.55 (2.90) 8.60 (2.98) * * * 
Serum bio-available 25(OH)D (nmol/L) 10.57 (2.91) 8.62 (2.99) * * * 
Serum free 25(OH)D (pmol/L) 26.3 (7.4) 21.5 (7.4) * * * 
DBP-bound 25(OH)D (nmol/L) 68.96 (19.68) 57.39 (19.04) * * * 
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 In principle, our results are in agreement with 
those reported by Powe et  al. [23], who examined 49 
male and female students, 18 – 31 years old. In this 
cohort, they found free and bio-available 25(OH)D 
to signifi cantly correlate with BMD, whereas this was 
not seen for total 25(OH)D. However, in their study 
there was no relation with PTH, probably due to the 
low number of subjects included. Furthermore, in 
94 subjects on hemodialysis Bhan et  al. found bio-
available 25(OH)D, but not total 25(OH)D, to be 
signifi cantly associated with the PTH levels [25]. On 
the other hand, Dastani et  al. in a study on 2073 
subjects found the relation between 25(OH)D and 
PTH to be independent on the DBP concentration 
[26] , and accordingly, this matter is not settled. 
 Since the calculation of free and bio-available 
25(OH)D is dependent on the binding coeffi cient 
for DBP, one would expect that the use of DBP 
phenotype-specifi c binding coeffi cients would 
improve the relations between free and bio-available 
25(OH)D and the vitamin D-related effects. In our 
study this caused an increase in the standardized 
beta-coeffi cients regarding BMD total hip. Thus, 
only the  ‘ SNP-adjusted ’ free and bio-available 
25(OH)D showed a signifi cant association. However, 
this was not seen for the association with PTH, which 
was slightly surprising in view of the close to 40% 
effect the  ‘ SNP-adjustment ’ had on the serum free 
and bio-available 25(OH)D levels. 
 If the free and/or bio-available 25(OH)D forms 
of 25(OH)D are those with the highest biological 
activity, one would expect that high levels of DBP 
would inhibit the action of vitamin D. This has been 
demonstrated in cultures of monocytes, keratino-
cytes and T cells [27 – 30], and a negative association 
between DBP and BMD has previously been pub-
lished by Powe et  al. [23]. This was also seen in our 
study for total body and total hip BMD measure-
ments. Most likely this effect is due to binding and 
inhibition of 25(OH)D, but could also be due to 
direct effects of DBP on bone metabolism. 
 Different associations between BMD and 25(OH)
D have been reported, and varies greatly depending 
on sex, age, weight and ethnicity [12,14,31]. 
Discrepancies regarding BMD and 25(OH)D related 
to ethnicity could possibly be explained by  DBP 
polymorphisms [32]. Thus, it would be very interest-
ing to use this  ‘ SNP-adjustment ’ method in a popu-
lation of mixed ethnicity. 
 To the best of our knowledge albumin is not a 
polymorphic protein regarding binding coeffi cients for 
vitamin D metabolites, and  ‘ SNP-adjustment ’ for 
albumin was therefore not performed. Furthermore, 
the serum albumin levels were not negatively associ-
ated with BMD or PTH which may indicate that albu-
min, although it contributes to 25(OH)D transportation 
in the circulation, does not bind 25(OH)D to such an 
extent that the biological effect is blocked. 
 Our study has a number of shortcomings. Firstly, 
we studied a highly selected group, postmenopausal 
women with reduced bone density, and our results 
may therefore not apply to the general population. 
Secondly, we assumed a (C1  !  C2)/2 relationship 
when calculating the binding coeffi cient of the  DBP 
diplotypes, where C represents haplotype. We can-
not exclude that the haplotypes have an infl uence on 
each other ’ s binding coeffi cient and ideally, the six 
different binding coeffi cients should have been 
determined experimentally. Another approach would 
be to measure the free and bio-available forms in 
 Table III. Standardized beta-coeffi cients and  r 2 values from the linear regression model with age and BMI as covariates. 
 
Dependent variables
Total BMD BMD L1-L4
BMD Total 
hip Plasma PTH
Subjects not taking vitamin D or calcium supplements ( n  &  168)
Serum total 25(OH)D 0.078 0.016 0.031  #  0.295 * * * 
Serum free 25(OH)D 0.167 * 0.033 0.130  #  0.298 * * * 
Serum free 25(OH)D SNP adjusted 0.204 * * 0.013 0.144 *  #  0.224 * * 
Serum bio-available 25(OH)D 0.168 * 0.025 0.136  #  0.297 * * * 
Serum bio-available 25(OH)D SNP adjusted 0.205 * * 0.007 0.152 *  #  0.224 * * 
Serum DBP  #  0.249 * * *  #  0.074  # 0.242 * * 0.077
Serum albumin 0.011  #  0.098 0.065  #  0.043
 r 2 0.195 – 0.254 0.025 – 0.034 0.192 – 0.229 0.029 – 0.115
Subjects taking vitamin D or calcium supplements ( n  &  97)
Serum total 25(OH)D  #  0.096  #  0.067 0.097  #  0.186
Serum free 25(OH)D  #  0.103  #  0.061 0.169  #  0.164
Serum free 25(OH)D SNP adjusted 0.023 0.067 0.101  #  0.294 * * * 
Serum bio-available 25(OH)D  #  0.085  #  0.058 0.198 *  #  0.162
Serum bio-available 25(OH)D SNP adjusted 0.033 0.065 0.121  #  0.294 * * 
Serum DBP 0.071  #  0.020  #  0.152  #  0.019
Serum albumin 0.110 0.015 0.134 0.042
 r 2 0.095 – 0.105 0.028 – 0.032 0.089 – 0.108 0.040 – 0.126
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specifi c assays, which at least for free 25(OH)D, 
hopefully will be available in the near future. And 
fi nally, the results were not completely consistent at 
all BMD measurement sites and need confi rmation 
in other studies. 
 On the other hand, we included a fairly large 
group of subjects and made adjustments and strati-
fi ed for relevant confounders. Also, adjusting the free 
and bio-available 25(OH)D levels for the different 
DBP binding coeffi cients is a novel and biologically 
logical approach. 
 The results of the study may have important 
clinical consequences. The free and/or bio-available 
fractions of 25(OH)D may be more strongly linked 
to important biological effects than the total fraction 
and may be benefi cial to assess for certain patient 
groups, such as postmenopausal females or others at 
risk of osteoporosis or low BMD. However, DBP is 
an expensive analysis. The increasing volume of 
25(OH)D analyses being performed does not allow 
measurement and calculation of free and/or bio-
available 25(OH)D instead of total 25(OH)D for the 
general patient groups without a considerable cost. 
Genotyping of specifi c DBP phenotypes in order to 
more correctly calculate the free and/or bio-available 
25(OH)D levels, would increase the costs of analysis 
even further. 
 In conclusion, our results indicate that free and 
bio-available 25(OH)D may be a more informative 
measure of the vitamin D status in relation to BMD, 
and also that adjusting for DBP phenotype may be 
a further improvement. However, the fi ndings need 
confi rmation in larger studies. 
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